Rheonix Inc. Receives FDA Emergency Use Authorization for Rapid, Fully Automated Molecular COVID-19 Test
Sample-to-answer method will enable rapid testing in distributed locations
Read Press Release
Read Letter of Authorization
Mayor Richard C. David on Thursday joined John Carrigg, President and CEO of United Health Services (UHS), and Gregory J. Galvin, Ph.D., President and CEO of Rheonix Inc., to announce a same-day COVID-19 virus testing partnership between the City of Binghamton and United Health Services.
Read More »
Cayuga Medical Center to be First Hospital in NY State to Use This New Technology
Read More »
Ithaca, N.Y. — April 16, 2010 — Rheonix, Inc. today announced that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), continues to support its Point-of-Care Partnership with Rheonix for a second year. As part of the grant, Rheonix will receive an additional $396,775 award to optimize its CARD™ (Chemistry And Reagent Device) diagnostic platform for simultaneous, multiplex, point-ofcare detection of the… Read More »
Ithaca, N.Y. — Tuesday, January 19, 2010 — Rheonix, Inc. today announced the receipt of a National Science Foundation (NSF) Small Business Innovation Research Phase IB grant. The award decision recognizes the substantial progress made by Rheonix during the NSF-funded Phase I program to develop a rapid biosensor to monitor recreational water safety and the Company’s ability to attract significant funding from the New York State Energy Research and Development… Read More »
Ithaca, NY — Tuesday, January 12, 2010 — Rheonix, Inc. announced that on October 27, 2009 the U. S. Patent and Trademark Office issued Patent Number 7,608,160, Laminated Microfluidic Structures and Method for Making, the first grant of U. S. patent rights for the Company’s microfluidic lamination technology. A patent claiming the same technology has also issued in China.
“These patents recognize the unique contribution that inventors Dr. Peng Zhou and… Read More »
Ithaca, N.Y. — June 8, 2009 — Rheonix, Inc. today announced the receipt of a $99,928 Small Business Innovation Research Phase I grant from the National Science Foundation (NSF) to develop a rapid test to monitor recreational water for safety. Upon successful completion of the six month Phase I program, Rheonix will be eligible to compete for additional Phase II funding to finalize the prototype test developed during the Phase… Read More »
Ithaca, N.Y. — May 13, 2009 — Rheonix, Inc. today announced the receipt of a $1.67 Million award from the National Institutes of Health (NIH) as the Company and NIH establish a partnership for the development of point-of-care (POC) technologies for underserved and nontraditional health care settings such as rural and urban community public heath-care clinics and temporary medical facilities established in response to natural or human-made disasters.
“This significant financial… Read More »
Ithaca, N.Y. — March 31, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, will receive a $100,000 Phase I grant from the National Institutes of Allergy and Infectious Diseases (NIAID) to develop a biosensor for the rapid detection of the causative agent of tuberculosis (TB) in human clinical specimens. The grant will come through NIAID’s Small Business Innovative Research (SBIR)… Read More »
Ithaca, N.Y. — March 17, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, announced an additional $120,000 award from the U.S. Environmental Protection Agency (EPA) to further commercialize its biosensor technology for the rapid detection of Cryptosporidium parvum in drinking water.
Cryptosporidium parvum can cause serious illness in infants and the elderly. The largest outbreak of the infection occurred in Milwaukee… Read More »
GRAND ISLAND, NY — December 31, 2008 — Richard A. Montagna, President of Innovative Biotechnologies International, Inc. ("IBI"), today announced the successful completion of an acquisition by privately-held, Ithaca, NY-based Rheonix, Inc. The ability to integrate the biosensor capabilities of IBI, developed in collaboration with scientists at Cornell University with Rheonix's novel CARD™ (Chemistry And Reagent Device) microfluidic technology, will provide a fully automated "point-of-care" (POC) or "point-of-use" (POU) diagnostic… Read More »
ITHACA, N.Y. – March 25, 2008 – Rheonix Inc., an in vitro diagnostics systems company pioneering single chip, fully-integrated microfluidic systems for near-patient and point-of-care molecular identification of infectious disease and other applications, announced that it has been selected by the New York State Senate and NYSTAR to receive one of two Innovations Awards, which will support the Company’s participation in Bio International 2008.
Founded in 2007, Rheonix’s technology is based… Read More »